P&T highlights the accomplishments of Dr. Afable, a board member since 2000.
You are here
P&T® Journal contents for June 2003
The FDA's mandate for improved pediatric labeling may lead to a much-needed increase in research for children's therapies.
Principles of Antibiotic Formulary Selection for P&T Committees: Overview — Part 1: Antimicrobial Activity
First things first: antimicrobial agents should have a high degree of activity against the pathogens they are intended to treat.
Continuing Education Credit
A new drug, omalizumab (Xolair™), appears to be effective in overcoming the difficulties in treating persistent and moderate-to-severe asthma.